Compare ELTX & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
| Metric | ELTX | NEN |
|---|---|---|
| Founded | 2011 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 209.2M |
| IPO Year | 2014 | 1995 |
| Metric | ELTX | NEN |
|---|---|---|
| Price | $3.60 | $57.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 1.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $89,196,544.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.68 |
| Revenue Growth | N/A | ★ 10.76 |
| 52 Week Low | $2.66 | $55.61 |
| 52 Week High | $16.00 | $74.00 |
| Indicator | ELTX | NEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 46.26 |
| Support Level | $2.66 | $56.83 |
| Resistance Level | $9.44 | $60.90 |
| Average True Range (ATR) | 0.82 | 1.29 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 20.93 | 47.40 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.